To improve access for beneficiaries, CMS has proposed a plan to increase the availability of preferred cost-sharing pharmacies in Medicare.
To improve access for beneficiaries, CMS has proposed a plan to increase the availability of preferred cost-sharing pharmacies in Medicare.
Last year, CMS was concerned that some beneficiaries did not have ready geographic access to preferred cost-sharing pharmacies. Add to that, Medicare Part D plans are creating smaller networks of pharmacies within their larger networks and offering lower cost-sharing arrangements to beneficiaries who use these preferred cost-sharing pharmacies.
While such lower cost-sharing arrangements seemed lucrative to the beneficiaries who wished to save money on their prescription drugs, in most instances, it wasn’t ideal because the pharmacies were not geographically accessible to the beneficiaries in the plan.
Bridging Geographical Gaps
CMS published an analysis of the availability of preferred cost-sharing pharmacies to Part D enrollees in April 2015. The report highlighted that most Part D enrollees lived in areas with accessibility to a robust preferred cost-sharing pharmacy network. However, the report also stressed on a shortcoming—a few beneficiaries, especially those living in urban areas, face limited or no geographic access to preferred cost-sharing pharmacies.
Consequently, CMS took action toward bridging the gap. They adopted a 3-pronged approach that included:
Through the collective efforts of CMS and Part D sponsors, the access to preferred cost-sharing pharmacies has significantly improved.
“The bottom 10th percentile of plans in 2016 offer access within two miles to 71% of urban beneficiaries, as compared to 40% of beneficiaries in 2014,” according to Sean Cavanaugh, deputy administrator and director of the Center for Medicare at CMS.
Scope for Improvement
The National Community Pharmacists Association (NCPA), however, didn’t express extreme joy with the report. Speaking on behalf of NCPA members and beneficiary advocates, the association issued a statement that CMS still needs to do more work to achieve its aim of improving access to beneficiaries.
B. Douglas Hoey, CEO of NCPA, believes that CMS may have overshot its total numbers because it excluded from this analysis plans that were granted waivers to the retail pharmacy convenient access standard requirement. The marketing disclaimers have also been released well after the 2016 enrollment period concluded and 6 weeks into the plan year.
Additionally, Hoey believes that the importance of the data should be incorporated into Medicare Plan Finder prominently—and before beneficiaries research their enrollment decisions.
“Since beneficiaries need swifter relief and protection, we encourage Medicare officials to implement the ‘any willing pharmacy’ policy,” Hoey added.
Through the realization of the any willing pharmacy act, beneficiaries in medically underserved areas will be presented with more access to their prescription drugs at a community pharmacy that accepts the drug plan's terms and conditions and can serve those patients.
“This would be the best way to boost price competition and lowering of costs in the Part D program,” Hoey said.
Bridging the Gaps: New Strategies for Preventing Cardiovascular Disease
July 31st 2025During the Addressing Cardiovascular Risk and Intervening Early webinar, experts discuss innovative strategies for cardiovascular disease prevention, emphasizing risk assessment, lifestyle changes, and collaborative care to improve patient outcomes.
Read More
Trends in Insulin Out-of-Pocket Costs and Use Disparities, 2008-2021
July 31st 2025Given trends in cost and use, insulin out-of-pocket cost reduction policies would be more efficient if they targeted members in high-deductible health plans with savings options and low-income patients.
Read More
The Legal Architecture of Psychedelic Therapy: Risks, Responsibilities, and Reimbursement Realities
July 30th 2025Key legal, ethical, and compliance considerations for managed care professionals navigating the evolving landscape of psychedelic-assisted therapy include regulatory risks, data privacy challenges, reimbursement limitations, and the need for culturally informed care models.
Read More